Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Conditions

• Poorly Differentiated Malignant Neuroendocrine Carcinoma
• Neuroendocrine Carcinoma, Grade 3
• Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3
• Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3
• Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)

Interventions

• DRUG: Everolimus (Afinitor®)

Sponsor

AIO-Studien-gGmbH

Collaborators

• [object Object]
• [object Object]